Security
Immuron Limited Warrants · IMRNW
IMRNWNASDAQWarrantHistorical · closed Jun 10, 2022CIK 1660046Updated Oct 29, 2026
IMRNW price & chart
Historical security
This listing closed Jun 10, 2022. Live provider charts are shown only for current listings.
About the company
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · AUDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossAUD | -5,215,987Source | -6,936,957Source | -3,786,507Source | -2,854,254Source |
| Additional Financial Items | ||||
| AdjustmentsForFinanceCostsAUD | 7,305Source | 7,576Source | 9,652Source | 6,184Source |
| AdjustmentsForFinanceIncomeAUD | 135,866Source | 327,756Source | 116,323Source | 21,785Source |
| AdjustmentsForSharebasedPaymentsAUD | 304,243Source | 3,299Source | — | — |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsAUD | 12,183Source | -76,771Source | -422,881Source | -234,794Source |
| GeneralAndAdministrativeExpenseAUD | 4,483,623Source | 4,555,726Source | 4,220,905Source | 3,524,388Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesAUD | 768,433Source | 395,001Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesAUD | 7,305Source | 7,576Source | 9,652Source | 6,184Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesAUD | 65,661Source | 15,595Source | 35,015Source | 36,264Source |
| ProceedsFromIssuingSharesAUD | — | 24,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Total RevenueAUD | 7,287,002Source | 4,902,865Source | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source | — |
| BasicEarningsLossPerShareAUD/shares | -2.26Source | -3.04Source | -1.66Source | -1.25Source |
| CurrentTaxExpenseIncomeAUD | — | — | -946,627Source | -713,564Source |
| DeferredTaxExpenseIncomeUSD | — | — | 698,195Source | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossAUD | — | — | 698,195Source | — |
| DepreciationAndAmortisationExpenseAUD | — | — | 48,662Source | 42,606Source |
| DepreciationRightofuseAssetsAUD | — | 40,066Source | 41,328Source | 37,937Source |
| DilutedEarningsLossPerShareAUD/shares | -2.26Source | -3.04Source | -1.66Source | -1.25Source |
| EmployeeBenefitsExpenseAUD | 2,120,614Source | — | — | — |
| FinanceCostsAUD | 7,305Source | 7,576Source | 9,652Source | 6,184Source |
| FinanceIncomeAUD | 135,866Source | 327,756Source | 116,323Source | 21,785Source |
| GeneralAndAdministrativeExpenseAUD | 4,483,623Source | 4,555,726Source | 4,220,905Source | 3,524,388Source |
| GrossProfitAUD | 4,765,099Source | 3,336,797Source | 1,309,147Source | 523,502Source |
| InterestExpenseOnLeaseLiabilitiesAUD | — | 7,576Source | 9,652Source | 6,100Source |
| NetForeignExchangeLossAUD | 5,178Source | — | — | — |
| OtherEmployeeExpenseAUD | — | — | 1,874,963Source | 1,212,721Source |
| OtherIncomeAUD | 1,411,505Source | 3,408,199Source | 2,591,498Source | 957,725Source |
| OtherOperatingIncomeExpenseAUD | 30,512Source | 15,760Source | — | — |
| ProfessionalFeesExpenseAUD | 69,068Source | — | — | — |
| ProfitLossAttributableToOwnersOfParentAUD | -5,215,987Source | -6,936,957Source | -3,786,507Source | -2,854,254Source |
| ProfitLossBeforeTaxAUD | -5,215,987Source | -6,936,957Source | -3,786,507Source | -2,854,254Source |
| ProfitLossFromOperatingActivitiesAUD | -5,344,548Source | -5,801,118Source | -3,568,838Source | -2,869,855Source |
| ResearchAndDevelopmentExpenseAUD | 3,597,296Source | 5,375,461Source | 2,592,145Source | 657,715Source |
| SellingExpenseAUD | 481,957Source | — | 192,878Source | 57,854Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodAUD | — | -1,456,019Source | -324,340Source | — |
| TaxRateEffectOfForeignTaxRatesnumber | 0.25Source | 0.25Source | 0.25Source | — |
Filing attachments
ea030992701ex99-1.htm · 6-K · 2026-10-28
Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, October 28, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting at the Emerging Growth Conference on Wednesday 28th October 2026 (4:25pm - 4:55pm U.S. Eastern Time). A copy of the presentation being made is included below. This release has been authorised by the directors of Immuron Limited. - - - END - - - C…
Read attachment ↗ea030975801ex99-1.htm · 6-K · 2026-10-27
Exhibit 99.1 Immuron continued quarterly sales growth Sales Highlights (unaudited): Global ● Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) ● Q1 sales up 5% on prior quarter Australia ● Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp) ● Q1 sales up 12% on prior quarter Canada ● Q1 sales AUD$0.1 million up 286% on prior comparative period (pcp) …
Read attachment ↗ea030935501ex99-1.htm · 6-K · 2026-10-22
Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, October 22, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Wednesday 28th October 2026 (4:25pm - 4:55pm U.S. Eastern Time). Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event. Please register here to…
Read attachment ↗ea030883401ex99-1.htm · 6-K · 2026-10-16
Exhibit 99.1 IMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2026 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT Date and Time of Meeting: Wednesday, 18 November 2026 at 2:00 pm AEDT Place of Meeting: The Offices of Acclime Australia Suite 1, Level 3, 62 Lygon Street, Carlton South, Vic 3053 If Shareholders are unable to attend the Meeting in person, they are encouraged to return the proxy form to the Company in accordance with the instructions thereon.…
Read attachment ↗ea030840601ex99-1.htm · 6-K · 2026-10-13
Exhibit 99.1 Travelan® Phase 2 Study Results Published Melbourne, Australia, October 13, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports. A copy of the publication can be accessed here: https://doi.org/10.1038/s41598-026-70974-9 The article titled, "A phase 2, randomized, placebo-controlled study to evaluate once-daily oral Travelan for the preven…
Read attachment ↗ea030539801ex4-10.htm · 20-F · 2026-09-24
Exhibit 4.10 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is made between Immuron Limited (“Client”) with a principal place of business at Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131, Australia and Pullan Consulting, (“Consultant”), with a principal place of business at 9360 W. Flamingo Rd, Suite 110-554, Las Vegas, Nevada 89147, USA. This agreement will be effective when signed by both parties. Recitals Whereas, Consultant has skills and knowledge in busines…
Read attachment ↗